posted
IGNT LOOKING GREAT TODAY LOOK FOR PRICE INCRERASES DURING POWER HOUR. ALSO HAD NEWS TODAY CHECK IT OUT
Ingen Technologies, Inc.
YUCAIPA, Calif., Oct. 1, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries announced today that the Company has received notification from its patent attorney, Donn Harms, regarding the publication of the Chinese patent for the Oxyview and the Oxyview Nasal Cannula.
Related Quotes Symbol Price Change IGNT.PK 0.01 +0.00
{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""} The designated Chinese patent application no. 200710005067.4 was officially issued and published on July 1, 2009 for the cannula gas flow meter referred to as "Oxyview".
The company's pending patents in Japan, Canada, and the European Communities are expected to issue in 2010.
Donn K. Harms is a Registered Patent Attorney also handling business and corporate law matters since 1988, with heavy emphasis on trademarks, copyrights, patents, and licensing matters. Mr. Harms is certified by the San Diego County Bar Association for trademarks, and is a former member of the American Bar Association Committee on Trademark Law for recommendations to the U.S. Congress. His San Diego based firm, American Patent and Trademark Law Center, is a professional association of independent registered patent attorneys and specializes in patent, trademark, copyright and related business and government contract matters with agents and associates throughout the world, including China and Russia, providing various types of domestic and international filing needs for their clients. The firm is registered to practice before the United States Patent & Trademark Office.
"Mr. Harms has been our patent attorney since 1997, and has effectively provided his services that have allowed for several issued patents, domestic and foreign. You could not find a more successful firm and patent attorney than Donn Harms. Our patents provide a higher valuation of our company and additional security to our intellectual property, specifically our new "gravity-independent" technology applied to the Oxyview products, and our "digital transmission" technology applied to our OxyAlert products. The world market for our products includes 600M patients requiring supplementary oxygen and home oxygen therapy. We have recently shown increased sales in the USA with demand of our Oxyview Nasal Cannula products, and we have the company positioned to enter markets in China, Europe, Japan, Canada and Australia for product distribution in early 2010 as an additional revenue stream for Ingen," stated Scott R. Sand, CEO and Chairman of the Board.
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
Posts: 221 | Registered: Sep 2009
| IP: Logged |
YUCAIPA, Calif., Oct. 1, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the Company has signed contracts with Emergo Group, Inc. to debut the Oxyview Nasal Cannula at the world's largest healthcare exhibitions.
Related Quotes Symbol Price Change IGNT.PK 0.00 +0.00
{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""} On November 18, 2009, Emergo Group will introduce the new Oxyview Nasal Cannula at MEDICA in Germany. MEDICA is the center of attraction for all those involved in the health care industry. More than 135,000 visitors from well over 100 countries are expected to again obtain information on all the current and future trends in in-patient and out-patient care at this annual event. With its extensive ancillary program, numerous special events, two major congresses and the largest product display in the industry, MEDICA is the hub of the medical trade.
Next, on January 25, 2010, the Emergo Group will introduce the new Oxyview Nasal Cannula at Arab Health. The Arab Health Exhibition & Congress is the largest healthcare exhibition in the Middle East, and the second largest in the world. Arab Health is viewed as a must-attend global event in the healthcare calendar. Established 35 years ago, it provides a platform for the world's leading manufacturers, wholesalers and distributors to meet the medical and scientific community in the Middle East and beyond.
Emergo is currently assisting Ingen with the development and implementation of an ISO 13485 quality management system which is a requirement for China, Japan, Canada and Europe. In addition to Europe (CE Marking), Emergo is compiling Ingen's Technical File and have been contracted to be the company's European Authorized Representative. This CE Certificate will allow Ingen to sell all European countries where CE Marking is mandatory, i.e. 31 countries to date. The CE Marking is the company's ticket to all of these countries and no other additional registrations are required accept for Italy which requires device notification for all devices placed on the Italian market.
Australia recognizes the CE Marking and therefore the approval and registration process in Australia is straightforward. Ingen is currently negotiating with an Australian distributor to market and sell the Oxyview Nasal Cannula in their country. Emergo has offices in Australia and has agreed to act as Ingen's Sponsor and register the Ingen devices with TGA. Upon receipt of the CE Marking certificate Ingen can register fairly quickly with the Australian TGA, as they recognize CE Marking.
"Ingen has interested acquirers according to the Pacific Pearl Group Inc., and company management has agreed to hold the buy-out price of no less than 10 cents a share," stated Thomas J. Neavitt, Chief Financial Officer.
Posts: 221 | Registered: Sep 2009
| IP: Logged |
posted
Emergo Group Agreed to Debut Ingen's Products Globally Ingen Management Agrees to Hold At 10 Cents a Share On Future Buy-Out
Press Release Source: Ingen Technologies, Inc. On Thursday October 1, 2009, 4:15 pm EDT Buzz up! 0 Print Companies:Ingen Technologies, Inc.
YUCAIPA, Calif., Oct. 1, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the Company has signed contracts with Emergo Group, Inc. to debut the Oxyview Nasal Cannula at the world's largest healthcare exhibitions.
Related Quotes Symbol Price Change IGNT.PK 0.0065 +0.0017
{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""} On November 18, 2009, Emergo Group will introduce the new Oxyview Nasal Cannula at MEDICA in Germany. MEDICA is the center of attraction for all those involved in the health care industry. More than 135,000 visitors from well over 100 countries are expected to again obtain information on all the current and future trends in in-patient and out-patient care at this annual event. With its extensive ancillary program, numerous special events, two major congresses and the largest product display in the industry, MEDICA is the hub of the medical trade.
Next, on January 25, 2010, the Emergo Group will introduce the new Oxyview Nasal Cannula at Arab Health. The Arab Health Exhibition & Congress is the largest healthcare exhibition in the Middle East, and the second largest in the world. Arab Health is viewed as a must-attend global event in the healthcare calendar. Established 35 years ago, it provides a platform for the world's leading manufacturers, wholesalers and distributors to meet the medical and scientific community in the Middle East and beyond.
Emergo is currently assisting Ingen with the development and implementation of an ISO 13485 quality management system which is a requirement for China, Japan, Canada and Europe. In addition to Europe (CE Marking), Emergo is compiling Ingen's Technical File and have been contracted to be the company's European Authorized Representative. This CE Certificate will allow Ingen to sell all European countries where CE Marking is mandatory, i.e. 31 countries to date. The CE Marking is the company's ticket to all of these countries and no other additional registrations are required accept for Italy which requires device notification for all devices placed on the Italian market.
Australia recognizes the CE Marking and therefore the approval and registration process in Australia is straightforward. Ingen is currently negotiating with an Australian distributor to market and sell the Oxyview Nasal Cannula in their country. Emergo has offices in Australia and has agreed to act as Ingen's Sponsor and register the Ingen devices with TGA. Upon receipt of the CE Marking certificate Ingen can register fairly quickly with the Australian TGA, as they recognize CE Marking.
"Ingen has interested acquirers according to the Pacific Pearl Group Inc., and company management has agreed to hold the buy-out price of no less than 10 cents a share," stated Thomas J. Neavitt, Chief Financial Officer.
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
Posts: 119 | From: new york | Registered: Sep 2009
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
